Ralinepag vs Treprostinil (Remodulin)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Ralinepag
Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.
NCT03626688 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).
Next expected readout: December 2026 · NCT03683186 (registry estimate)
Reported efficacy
Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)
Result source: NCT03626688
Treprostinil (Remodulin)
Marketed by United Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT06317805 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Ralinepag: 5 of 5 rows · Treprostinil (Remodulin): 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ralinepag | Treprostinil (Remodulin) |
|---|---|---|
| 6MWD - Change absolute change · m No placebo or comparator arm | -120 m @ 221wka,b,c,d NCT02279745 · Phase 2 · registry result, not featured evidence | 440.8 ma,b,c,d NCT03055221 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 44.4%e NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result15% NCT02279160 · Phase 2 · registry result, not featured evidence | n/a: no completion milestonee NCT03055221 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 15.6%e NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result— NCT02279160 · Phase 2 · registry result, not featured evidence | 10%e NCT03055221 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 46.7%e NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result10% NCT02279160 · Phase 2 · registry result, not featured evidence | 87.5%e NCT03055221 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | e headache 64.4% diarrhoea 37.8% pain in jaw 33.3% NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more resultheadache 77.5% (placebo 28.6%) nausea 50% (placebo 23.8%) diarrhoea 47.5% (placebo 14.3%) NCT02279160 · Phase 2 · registry result, not featured evidence | e abdominal discomfort 18.8% catheter site pain 18.8% cough 18.8% NCT03055221 · Phase 4 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 4.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ralinepag
Treprostinil (Remodulin)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (Remodulin)'s landscape